<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265875</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01</org_study_id>
    <nct_id>NCT01265875</nct_id>
  </id_info>
  <brief_title>Secretin Infusion for Pain Due to Chronic Pancreatitis</brief_title>
  <official_title>Secretin Infusion for Pain Due to Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChiRhoClin, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ChiRhoClin, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine if intravenous secretin administration in escalating doses three times
           daily for three days will improve the pain from CP at the time of infusion, after each
           infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.

        -  To validate the safety of intravenous secretin administration at the dosage indicated in
           this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      12 patients will be enrolled in this study. Patients will be only those treated at
      Dartmouth-Hitchcock Medical Center for the diagnosis of CP. The diagnosis of CP will be made
      by the PI based on standard clinical, radiographic and/or biochemical criteria. Patients must
      be taking prescribed opioid analgesics for the specific treatment of CP at the time of study
      enrollment. Only patients between the ages of 18-70 and capable of providing informed consent
      will be considered eligible for the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30.</measure>
    <time_frame>Baseline, Days 1, 2, 3, 4, 7, 30.</time_frame>
    <description>10 point visual analog scale. 0= no pain. 10= worst possible pain. Days 1, 2, 3 were infusion days that included 5 VAS scores each day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opiate Use at Baseline, Days 4 and 30.</measure>
    <time_frame>Baseline, Day 4, Day 30.</time_frame>
    <description>Daily opiate use (oral morphine equivalent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life at Baseline, Day 4 and Day 30.</measure>
    <time_frame>Baseline, Day 4, Day 30.</time_frame>
    <description>Sf-36 ranges from 0 to 151. Higher scores indicating worse outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events.</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score at Each Administered Dose.</measure>
    <time_frame>Days 1, 2, and 3.</time_frame>
    <description>10 point scare from 0-10 with higher scores meaning higher levels of pain. VAS score assessed after each dose was summarized over Days 1, 2, and 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>human secretin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Secretin</intervention_name>
    <description>Dose Escalation</description>
    <arm_group_label>human secretin</arm_group_label>
    <other_name>ChiRhoStim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, between the ages of 18-70 years old.

          2. Documented chronic pancreatitis as determined by CT scan, endoscopic ultrasound, MRCP
             and/or pancreatic function tests.

          3. If female, and not more than 1 year post-menopausal or surgically sterile, must use
             medically acceptable form of contraception or abstain from sexual activity during the
             study. Acceptable methods of birth control are: intrauterine device, implantable
             progesterone device, progesterone intramuscular injection, oral contraceptive (started
             at least one month prior to Screening Visit 1 and continuing for the duration of the
             trial), contraceptive patch, condoms with spermicide or abstinence.

          4. If a female of reproductive potential, receive counseling on pregnancy protection and
             effective contraception within 30 days prior to dosing with secretin.

          5. Negative serum pregnancy within 72 hours of secretin administration.

          6. Use of opioid analgesics for chronic pain from CP.

          7. Willing and able to sign written informed consent.

        Exclusion Criteria:

          1. Male or female &lt;18 or &gt;70 years of age.

          2. Abnormal serum amylase and/or lipase indicative of acute pancreatitis within 30 days
             of study enrollment.

          3. Exhibiting signs and/or symptoms of an episode of acute pancreatitis.

          4. Severe cardiac disease (stable or unstable angina, congestive heart failure,
             uncontrolled arrhythmias, implantable defibrillator, severe valvular disease, etc).

          5. Severe pulmonary disease (COPD, severe asthma, interstitial lung disease, etc).

          6. Severe renal disease (history of acute or chronic renal failure, dialysis dependent,
             baseline creatinine &gt;2.0 mg/dL).

          7. Previous adverse drug event to intravenous secretin.

          8. Ongoing illicit drug use or abuse.

          9. Ongoing moderate or severe alcohol use defined as greater than 8 oz beer, 8 oz wine
             and/or 1 oz liquor /day.

         10. Acute pancreatitis as defined by the Atlanta Classification definition (refer to Table
             1) within the previous two months or symptoms consistent with ongoing acute
             pancreatitis.

         11. Prior pancreatic surgery.

         12. Pregnant women, nursing mothers, or women of childbearing potential not employing
             appropriate contraception.

         13. Use of medication that can potentially cause pancreatitis, such as metronidazole,
             tetracycline, sulfonamides within 30 days prior to Visit 1.

         14. Any medical condition which, in the judgment of the investigator, renders
             participation in this study medically inadvisable.

         15. Participation in an investigational clinical study for a drug or medical device within
             30 days prior to Visit 1.

         16. Unwilling or unable to give written, informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy B Gardner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>July 29, 2013</results_first_submitted>
  <results_first_submitted_qc>February 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2016</results_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secretin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Human Secretin</title>
          <description>Human Secretin : Dose Escalation
There were 3 days of dosing, 3 doses per day. This was a dose escalation within the participant and did not exceed 0.8mcg/kg, which is within safe limits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Uncooperative/unreliable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Human Secretin</title>
          <description>Human Secretin : Dose Escalation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30.</title>
        <description>10 point visual analog scale. 0= no pain. 10= worst possible pain. Days 1, 2, 3 were infusion days that included 5 VAS scores each day.</description>
        <time_frame>Baseline, Days 1, 2, 3, 4, 7, 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Secretin</title>
            <description>Human Secretin : Dose Escalation</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30.</title>
          <description>10 point visual analog scale. 0= no pain. 10= worst possible pain. Days 1, 2, 3 were infusion days that included 5 VAS scores each day.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Dose 1 (.05mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Dose 2 (.1mcg/kg) 100 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Dose 3 (.2mcg/kg) 100 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Dose 3 (.2mcg/kg) 380 min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Dose 1 (.1mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Dose 2 (.2mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Dose 3 (.4mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Dose 3 (.4mcg/kg) 380min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Dose 1 (.2mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Dose 2 (.4mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Dose 3 (.8mcg/kg) 100min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 Dose 3 (.8mcg/kg) 380min post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.25</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to day 7.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.19</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Day 30.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.27</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events.</title>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Secretin</title>
            <description>Human Secretin : Dose Escalation
There were 3 days of dosing, 3 doses per day. This was a dose escalation within the participant and did not exceed 0.8mcg/kg, which is within safe limits.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Opiate Use at Baseline, Days 4 and 30.</title>
        <description>Daily opiate use (oral morphine equivalent).</description>
        <time_frame>Baseline, Day 4, Day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Secretin</title>
            <description>Human Secretin : Dose Escalation
There were 3 days of dosing, 3 doses per day. This was a dose escalation within the participant and did not exceed 0.8mcg/kg, which is within safe limits.</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Use at Baseline, Days 4 and 30.</title>
          <description>Daily opiate use (oral morphine equivalent).</description>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" spread="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.0" spread="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2" spread="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Day 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.52</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to Day 30.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.34</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quality of Life at Baseline, Day 4 and Day 30.</title>
        <description>Sf-36 ranges from 0 to 151. Higher scores indicating worse outcomes.</description>
        <time_frame>Baseline, Day 4, Day 30.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Secretin</title>
            <description>Human Secretin : Dose Escalation
There were 3 days of dosing, 3 doses per day. This was a dose escalation within the participant and did not exceed 0.8mcg/kg, which is within safe limits.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life at Baseline, Day 4 and Day 30.</title>
          <description>Sf-36 ranges from 0 to 151. Higher scores indicating worse outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.92" spread="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.9" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.45" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score at Each Administered Dose.</title>
        <description>10 point scare from 0-10 with higher scores meaning higher levels of pain. VAS score assessed after each dose was summarized over Days 1, 2, and 3.</description>
        <time_frame>Days 1, 2, and 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Human Secretin</title>
            <description>Human Secretin : Dose Escalation
There were 3 days of dosing, 3 doses per day. This was a dose escalation within the participant and did not exceed 0.8mcg/kg, which is within safe limits.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score at Each Administered Dose.</title>
          <description>10 point scare from 0-10 with higher scores meaning higher levels of pain. VAS score assessed after each dose was summarized over Days 1, 2, and 3.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.05 mcg/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.1 mcg/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.2 mcg/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.4 mcg/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>.8 mcg/kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Human Secretin</title>
          <description>Human Secretin : Dose Escalation within participant</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, nausea, vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>epigastrium and right upper quadrant pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Central line infection (coagulase negative S. Aureus infection with bacteremia)</sub_title>
                <description>Previous Hx central line infections. The SAE was related to a PICC line positioned in the R subclavian vein to provide the patient with TPN required by a Dx of CP related to alcohol abuse. Only subject in study with central line so only one at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea, mild</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>mild flushing, upper body</sub_title>
                <description>Flushing is listed as a side effect in the package insert for human secretin.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Gardner, MD</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-6472</phone>
      <email>timothy.b.gardner@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

